Table 2.

Baseline disease characteristics of pooled dupilumab-treated “achiever” and “non-achiever” patients from SOLO 1 and 2

IGA 0/1 or EASI-75 at 16 weeks	SOLO 1 and 2 dupilumab-treated patients
	Non-achievers (n = 391)	Achievers (n = 529)
Duration of AD, years, mean ± SD	29.1 (15.0)	26.7 (15.4)
IGA score (range 0–4), mean ± SD	3.6 (0.5)	3.4 (0.5)
EASI total score (range 0–72), mean ± SD	35.7 (14.1)	29.9 (12.1)
Weekly peak pruritus NRS (range 1–10), mean ± SD	6.5 (1.8)	6.4 (2.0)
BSA affected (range 0–100), mean ± SD	58.9 (22.6)	50.0 (21.3)
POEM total score (range 0–28), means ± SD	21.4 (5.8)	19.8 (6.0)
Prior use of systemic immunosuppressants (including corticosteroids), n (%)	234 (59.8)	238 (45.0)

AD atopic dermatitis, BSA Body Surface Area Index, EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, NRS numerical rating scale, POEM Patient-Oriented Eczema Measure, SD standard deviation